MX2020002711A - Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. - Google Patents

Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.

Info

Publication number
MX2020002711A
MX2020002711A MX2020002711A MX2020002711A MX2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A
Authority
MX
Mexico
Prior art keywords
dimethylimidazo
octan
pyridazin
pyrido
pyrimidin
Prior art date
Application number
MX2020002711A
Other languages
English (en)
Inventor
Serena Maria Fantasia
Christophe Pfleger
Daniel Vincent Fishlock
Fabienne Hoffmann-Emery
Jean-Michel Adam
Gerard Moine
Christian Moessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020002711A publication Critical patent/MX2020002711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74—Iron group metals
    • B01J23/755—Nickel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de derivados de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetili midazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona útiles como compuestos farmacéuticamente activos.
MX2020002711A 2017-09-22 2018-09-19 Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. MX2020002711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192711 2017-09-22
PCT/EP2018/075282 WO2019057740A1 (en) 2017-09-22 2018-09-19 PROCESS FOR THE PREPARATION OF 7- (4,7-DIAZASPIRO [2.5] OCTAN-7-YL) -2- (2,8-DIMETHYLIMIDAZO [1,2-B] PYRIDAZIN-6-YL) PYRIDO [1,2-DERIVATIVES] ] pyrimidin-4-ONE

Publications (1)

Publication Number Publication Date
MX2020002711A true MX2020002711A (es) 2020-07-20

Family

ID=59955477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002711A MX2020002711A (es) 2017-09-22 2018-09-19 Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.

Country Status (16)

Country Link
US (3) US11390632B2 (es)
EP (2) EP4663641A3 (es)
JP (2) JP7075484B2 (es)
KR (2) KR102691657B1 (es)
CN (2) CN116813648A (es)
AR (1) AR112828A1 (es)
AU (1) AU2018337597B2 (es)
CA (1) CA3075968C (es)
ES (1) ES3056885T3 (es)
HR (1) HRP20251594T1 (es)
IL (1) IL273268B2 (es)
MX (1) MX2020002711A (es)
PL (1) PL3684766T3 (es)
SG (1) SG11202002610TA (es)
TW (1) TWI812646B (es)
WO (1) WO2019057740A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002610TA (en) * 2017-09-22 2020-04-29 Hoffmann La Roche Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
JP2022505098A (ja) 2018-10-19 2022-01-14 エフ．ホフマン－ラ ロシュ アーゲー ピリド［１，２－ａ］ピリミジン－４－オン誘導体の新規な形態、その製剤およびその製造プロセス
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
MX2023010719A (es) 2021-03-17 2023-09-20 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona.
WO2022194802A1 (en) 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiadiazolopyrimidone derivatives
WO2022194909A2 (en) * 2021-03-18 2022-09-22 F. Hoffmann-La Roche Ag Novel process
AU2023232386A1 (en) 2022-03-10 2024-08-29 F. Hoffmann-La Roche Ag Pyrido[1,2-a]pyrimidin-4-one derivatives
WO2024003798A1 (en) * 2022-06-29 2024-01-04 Biophore India Pharmaceuticals Pvt. Ltd. A novel process for the preparation of 7 (4, 7- diazaspiro [2.5] octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b] pyrid azin-6- yl) pyrido-4h-[1,2-a] pyrimidin-4-one with novel intermediates
US20260098048A1 (en) * 2022-09-26 2026-04-09 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
CN120530115A (zh) * 2023-01-21 2025-08-22 哈曼菲诺化学有限公司 利司扑兰的制备方法、新型中间体及其制备方法
CN121219298A (zh) 2023-04-20 2025-12-26 豪夫迈·罗氏有限公司 噻吩并[3,2-b]吡啶衍生物
WO2024236590A1 (en) * 2023-05-13 2024-11-21 Harman Finochem Limited Novel crystalline form of risdiplam and process for preparation thereof
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
CN116947865B (zh) * 2023-08-11 2025-06-13 扬州联澳生物医药有限公司 一种利司扑兰中间体的合成方法和利司扑兰中间体
WO2025057179A1 (en) * 2023-09-12 2025-03-20 Harman Finochem Limited A process for purification of risdiplam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352861B (es) 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
EP2812004B1 (en) 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
ES2761423T3 (es) * 2014-05-15 2020-05-19 Hoffmann La Roche Compuestos para tratar la atrofia muscular espinal
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2017081111A1 (en) 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis
EA036399B1 (ru) 2015-11-12 2020-11-06 Ф. Хоффманн-Ля Рош Аг Композиции для лечения спинальной мышечной атрофии
SG11202002610TA (en) * 2017-09-22 2020-04-29 Hoffmann La Roche Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
CN116813648A (zh) 2023-09-29
ES3056885T3 (en) 2026-02-25
JP7398510B2 (ja) 2023-12-14
US11390632B2 (en) 2022-07-19
JP2022107003A (ja) 2022-07-20
JP7075484B2 (ja) 2022-05-25
IL273268B1 (en) 2023-01-01
SG11202002610TA (en) 2020-04-29
US20250084102A1 (en) 2025-03-13
HRP20251594T1 (hr) 2026-01-30
IL273268A (en) 2020-04-30
AU2018337597B2 (en) 2021-03-25
CA3075968A1 (en) 2019-03-28
EP4663641A2 (en) 2025-12-17
US20220324881A1 (en) 2022-10-13
US12122791B2 (en) 2024-10-22
PL3684766T3 (pl) 2026-02-23
IL273268B2 (en) 2023-05-01
KR20230020580A (ko) 2023-02-10
EP3684766A1 (en) 2020-07-29
TW201920205A (zh) 2019-06-01
BR112020005549A2 (pt) 2020-10-06
AR112828A1 (es) 2019-12-18
TWI812646B (zh) 2023-08-21
KR102691657B1 (ko) 2024-08-05
CN111132981A (zh) 2020-05-08
EP3684766C0 (en) 2025-10-29
EP4663641A3 (en) 2026-01-07
KR20200058468A (ko) 2020-05-27
US20200216472A1 (en) 2020-07-09
CN111132981B (zh) 2023-10-31
CA3075968C (en) 2023-04-04
WO2019057740A1 (en) 2019-03-28
AU2018337597A1 (en) 2020-03-26
JP2020534330A (ja) 2020-11-26
EP3684766B1 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
AR131260A2 (es) Compuestos para tratar atrofia muscular espinal
PL3555097T3 (pl) Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych
WO2013128028A8 (en) Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors
EP2580214A4 (en) 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
MX352831B (es) Cristales de sal.
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL243269A0 (en) Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts.
IL268923A (en) History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
MX2019005123A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
BR112023018593A2 (pt) Processo
HK1257197A1 (zh) 用於制备 fgfr 抑制剂的方法
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
HK40130482A (zh) 制备咪唑并[1，2-a]吡咯并[2，3-e]吡嗪类化合物及其固态形式的方法
HK40130483A (zh) 制备咪唑并[1，2-a]吡咯并[2，3-e]吡嗪类化合物及其固态形式的方法